DRTS — ALPHA TAU MEDICAL LTD
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ALPHA TAU MEDICAL LTD (DRTS)
ALPHA TAU MEDICAL LTD (DRTS) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Cathie Wood (ARK Investment Management), valued at $2M. Across recent filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in DRTS
How many top investors track DRTS
A small number of top investors own this.
DRTS Ownership Composition
How ALPHA TAU MEDICAL LTD is held across tracked investor types, based on reported 13F positions.
- Growth Funds61.0%
- Other39.0%
Tracked investors reporting DRTS
- Cathie WoodMar 31, 2026ARK Investment ManagementShares292.1KValue$2.1M% Portfolio0.02%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares140.4KValue$992.6K% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares46.4KValue$328.4K% Portfolio0.00%
Recent activity
- $533.7KFeb 17, 2026
- $328.4KMay 15, 2026
- New$992.6KMay 15, 2026
- New$2.1MMay 12, 2026
- Sold$0(-100.00%)Feb 17, 2026
- New$273.3KNov 14, 2025
Frequently asked questions
- How many institutional investors hold DRTS?
- 3 tracked institutional investors disclosed a position in DRTS (ALPHA TAU MEDICAL LTD) in their most recent 13F filing.
- Who is the largest institutional holder of DRTS?
- Cathie Wood, ARK Investment Management, holds the largest disclosed position in DRTS, valued at $2M.
- Did institutional ownership of DRTS increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 1 fully exited DRTS.
- Where does this DRTS ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.